> ## Content Index > Fetch the complete content index at: https://newsletters.qs.com/llms.txt > Use this file to discover other available public pages before exploring further. # 🫀 Health Futures #30 - URL: https://newsletters.qs.com/health-futures-29-copy/ - Published: 2024-08-12T11:30:22.000Z - Updated: 2024-08-12T11:30:22.000Z - Description: HolonIQ's Health Newsletter dives into the latest developments in chronic disease managemet, AI in Health, and genomics and highlights the week's top health deals. - Author: QS - Tags: Health Skills **Happy Monday 👋** Major themes this week included developments surrounding targeted chronic disease management, AI, and genomics. Doctors [raised](https://health.economictimes.indiatimes.com/news/industry/that-weight-loss-pill-comes-with-side-effects-consult-us-before-you-take-them-say-doctors/112258318?ref=newsletters.qs.com) concerns over the increment of weight-loss drug misuse. Eli Lilly experimental drug trizepatiude [enhanced](https://pharmaphorum.com/news/lilly-gets-first-heart-outcomes-readout-tirzepatide?ref=newsletters.qs.com) the use of GLP-1 beyond treating diabetes and obesity, including that North Carolina health experts [proposed](https://www.statnews.com/pharmalot/2024/08/06/roche-novo-lilly-weight-obesity-wegovy-ozempic-zepbound-henrietta-lacks-novartis-viatris-india-bristol-opioids-biomarin-hemophilia-fda-agenus/?ref=newsletters.qs.com) HHS negotiate in order to produce lower-cost alternatives. AI is rapidly integrating into healthcare, Simplify Healthcare [partners](https://finance.yahoo.com/news/simplify-healthcare-welcomes-innova-solutions-143100112.html?guccounter=1&ref=newsletters.qs.com) with Innova Solutions intended to provide AI health payer solutions, while J&J [secured](https://pharmafile.com/news/johnson-johnsons-medtech-announce-orthopaedics-receives-501k-clearance-from-fda-for-spinal-robotics-and-navigation-platform/?ref=newsletters.qs.com) FDA approval for surgical robotics systems that are active in spinal procedures. The pharmaceutical industry faces setbacks with terminated partnerships, BMS handed its rights to a TIGIT drug[ team up ](https://pharmaphorum.com/news/bms-ducks-out-156bn-tigit-alliance-agenus?ref=newsletters.qs.com)with Agenus ending its $1.56B partnership. Abbvie [acquired ](https://www.pharmaceutical-technology.com/news/abbvie-cerevel-therapeutics/?ref=newsletters.qs.com)Cerevel Therapeutics, a biopharmaceutical firm, in a $8.7B deal. ## 🎯Targeted Chronic Disease Management ⚠️ **Doctors warned about the risks of unprescribed weight-loss pills.** Doctors raised concerns over the[ increasing](https://health.economictimes.indiatimes.com/news/industry/that-weight-loss-pill-comes-with-side-effects-consult-us-before-you-take-them-say-doctors/112258318?ref=newsletters.qs.com) use of weight-loss drugs like semaglutide by people without proper medical supervision or prescription, highlighting the potential side effects. 🫀 **Eli Lilly reported experimental drug tirzepatide reduced the risk of worsening heart disease.** The experimental drug tirzepatide [reduced](https://pharmaphorum.com/news/lilly-gets-first-heart-outcomes-readout-tirzepatide?ref=newsletters.qs.com) the risk of heart failure in obese patients in a phase 3 clinical trial. This expands the potential use of GLP-1 agnoists beyond diabetes and obesity to inculde cardiovascular diseases. **💊 North Carolina seeked lower-cost obesity drug alternatives.** North Carolina officials are [urging ](https://www.statnews.com/pharmalot/2024/08/06/roche-novo-lilly-weight-obesity-wegovy-ozempic-zepbound-henrietta-lacks-novartis-viatris-india-bristol-opioids-biomarin-hemophilia-fda-agenus/?ref=newsletters.qs.com)the U.S. Department of Health and Human Services to negotiate licenses with obesity drug manufacturers in order to make lower-cost alternatives available. This is in the context of a abtuptly canceling Roche trial and low venture capital funding for biotech companies. ## 🤖 AI in Health 🔬**Indica Labs launched AI-powered macrodissection tool.** Indica Labs, a provider of AI-powered digital pathology solutions, [launched](https://www.med-technews.com/news/Digital-in-Healthcare-News/indica-labs-announces-launch-of-ai-powered-macrodissection-suite/?ref=newsletters.qs.com) Lung Macrodissect AI, a tool that aimed to better slide macrodissection and molecular pathology workflows. 🤝**Simplify Healthcare partners with Innova Solutions for AI-driven health payer solutions.** Simplify Healthcare, a provider of SaaS solutions for health insurance companies, announced a [partnership](https://finance.yahoo.com/news/simplify-healthcare-welcomes-innova-solutions-143100112.html?guccounter=1&ref=newsletters.qs.com) with Innova Solutions, signaling the interest of insurance providers to incoporate AI into their practices. **🤖Johnson & Johnson secured FDA approval for surgical robotics system.** Johnson & Johnson's MedTech division DePuy Synthes [received ](https://pharmafile.com/news/johnson-johnsons-medtech-announce-orthopaedics-receives-501k-clearance-from-fda-for-spinal-robotics-and-navigation-platform/?ref=newsletters.qs.com)FDA clearance for their surgical robotics system VELYS active, which is used in spinal procedures. ## 🧬 Genomics **💉 SK pharmteco partners with Rznomics for RNA Gene Therapy Development.** SK Pharmteco, a pharmaceutical company, entered into an MOU [agreement](https://www.pharmaceutical-technology.com/news/crznomics-gene-therapies/?ref=newsletters.qs.com) with Rznomics, a South Korean biotech firm, to collaborate on the development and production of RNA-based gene therapies. 💔 **BMS ended a $1.56B TIGIT cancer therapy deal with Agenus.** Bristol Myers Squibb [ended](https://pharmaphorum.com/news/bms-ducks-out-156bn-tigit-alliance-agenus?ref=newsletters.qs.com) its $1.56B alliance with Agenus to develop TIGIT immuno-oncology cancer therapies, handing back rights to an Agenus drug candidate that was licensed in 2021. 🧬 **Sangamo partners with Genentech to develop genomic medicines for neurodegenerative diseases.** Sangamo Therapeutics and Genentech entered into a license [agreement](https://www.businesswire.com/news/home/20240806084723/en/Sangamo-Therapeutics-Announces-Global-Epigenetic-Regulation-and-Capsid-Delivery-License-Agreement-with-Genentech-to-Develop-Novel-Genomic-Medicines-for-Neurodegenerative-Diseases?ref=newsletters.qs.com) to develop novel genomic medicines using epigenetic regulation and capsid delivery technologies for neurodegenerative diseases. ## **💰** Deals of the Week **💊 AbbVie**, a major pharmaceutical company, acquired **Cerevel Therapeutics**, a biopharmaceutical firm, in a [$8.7B](https://www.pharmaceutical-technology.com/news/abbvie-cerevel-therapeutics/?ref=newsletters.qs.com) deal. Through this acquisition Abbvie will strengthen its neuroscience portfolio by adding combined assets through Cerevel’s pipeline. **💉 Symbiotic Capital**, a CA-based life science credit firm, secured with more than [$600M ](https://vcwire.tech/2024/08/06/symbiotic-capital-launches-with-more-than-600m-raised/?ref=newsletters.qs.com)in capital committed. The company intends to use funds will structure and originate credit solutions to established life science companies to support scientific innovation. 🪙 **CooperSurgical** acquired **obp Surgical**, a US-based medical-based medical device company, in a deal valued at [$100M](https://www.medicaldevice-network.com/news/coopersurgical-obp-acquisition/?ref=newsletters.qs.com). This acquisition will further expand CooperSurgical’s portfolio with single-use surgical devices. 👑 **Red Queen Therapeutics**, a Cambridge, MA-based clinical-stage biotechnology company, raised[ $55M in Series A](https://www.citybiz.co/article/586560/red-queen-therapeutics-raises-55m-series-a/?ref=newsletters.qs.com) funding. The company intends to use the funds to expand operations and its development efforts. 🗺️ **Guidehealth**, an AI-enabled value-based care provider for health systems, announced it closed a [$14M](https://www.mobihealthnews.com/news/guidehealth-scores-14m-backing-memorial-hermann-health-system?ref=newsletters.qs.com) seed funding round. Gudehealth intends to use the funds to enhance its datasets and services. --- **Thank you for reading. Have a great week ahead!** Have some feedback or suggestions? Let us know at hello@holoniq.com [ ](https://newsletters.qs.com/psychedelic-mental-health-treatments-south-asia-health-tech-100-2/)